- Mar 2025
-
pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov
-
Study: Functional study
Model: HEK293 cell lines
Variant: VWF NM_000552.5: c.7664C>G, p.(Pro2555Arg), described as GOF mutation
rare missense variant, MAF = 0.00007
RefSNP_ID:rs915754316
Not reported in ClinVar
Cells lines were transfected and expressed one of the following: wtVWF, p.Pro2555Arg, both variants, or a negative control variant p.Asp2509Glu
Main result:
p.Pro2555Arg is the first VWF GOF variant that increases platelet aggregate size (AS), which is shear-dependent and independent of fibrinogen (fb). May provide a novel risk factor for thromboembolic disease.
Additional results:
Variant does not affect the binding affinity of the C4 domain for BPIIb/IIIa
VWF stem region mutations can enhance VWF's prothrombotic properties
C4 domain of VWF may be a novel antithrombotic drug target.
-
- Sep 2024
-
www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
-
functional assays
Chemiluminescence assays (measuring binding capacity)
VWF-collagen binding assay (CBA)
Electrophoresis (Western blot)
Bidirectional direct sequencing of PCR products
Paternity test
PCR and restriction assays to detect SNVs
in vitro expression of recombinant WT and p.P1127S VWF variants in HEK293 cells
Platelet aggregation studies
DDAVP test
Binding assays
Proteolysis assays
in silico modeling
-
-
www.ncbi.nlm.nih.gov www.ncbi.nlm.nih.gov
-
Our patient
Patient phenotypes listed: mild bleeding history normal platelet number increased mean platelet volume increased RIPA (les than typical PT-VWD) enhanced binding of VWF to platelets (assessed by flow cytometry)
Has functional and HXMS data to support classification to pathogenic
-
heterozygous c.G380A variant in GP1BA (NM_000173.7) (Figure 1B), resulting in a missense substitution of an arginine with a glutamine at position 127
Disease: platelet-type von Willebrand disease (PT-VWD)
Patient: 14 yo, Male
Variant: GP1BA NM_000173.7:c.389G>A p.(Arg127Gln), Heterozygous, Gain-of-Function (GOF)
Located in LRR5 domain of GP1BA
Family: Mother did not refer any bleeding symptoms (variant absent in mother) Father not available for collection of clinical history or platelet function testing
-
- Apr 2022
-
www.bmj.com www.bmj.com
-
Pavord, S., Hunt, B. J., Horner, D., Bewley, S., & Karpusheff, J. (2021). Vaccine induced immune thrombocytopenia and thrombosis: Summary of NICE guidance. BMJ, 375, n2195. https://doi.org/10.1136/bmj.n2195
-
- Aug 2021
-
-
Greinacher, A., Thiele, T., Warkentin, T. E., Weisser, K., Kyrle, P. A., & Eichinger, S. (2021). Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. New England Journal of Medicine, 384(22), 2092–2101. https://doi.org/10.1056/NEJMoa2104840
-
- Apr 2021
-
www.theguardian.com www.theguardian.com
-
the Guardian. ‘How UK Doctor Linked Rare Blood-Clotting to AstraZeneca Covid Jab’, 13 April 2021. http://www.theguardian.com/society/2021/apr/13/how-uk-doctor-marie-scully-blood-clotting-link-astrazeneca-covid-jab-university-college-london-hospital.
-